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Abstract
Cutaneous leishmaniasis (CL) is caused by Leishmania infection of dermal macrophages and is associated with chronic
inflammation of the skin. L. aethiopica infection displays two clinical manifestations, firstly ulcerative disease, correlated to a
relatively low parasite load in the skin, and secondly non-ulcerative disease in which massive parasite infiltration of the
dermis occurs in the absence of ulceration of epidermis. Skin ulceration is linked to a vigorous local inflammatory response
within the skin towards infected macrophages. Fas ligand (FasL) and Tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) expressing cells are present in dermis in ulcerative CL and both death ligands cause apoptosis of
keratinocytes in the context of Leishmania infection. In the present report we show a differential expression of FasL and
TRAIL in ulcerative and non-ulcerative disease caused by L. aethiopica. In vitro experiments confirmed direct FasL- and
TRAIL-induced killing of human keratinocytes in the context of Leishmania-induced inflammatory microenvironment.
Systemic neutralisation of FasL and TRAIL reduced ulceration in a model of murine Leishmania infection with no effect on
parasitic loads or dissemination. Interestingly, FasL neutralisation reduced neutrophil infiltration into the skin during
established infection, suggesting an additional proinflammatory role of FasL in addition to direct keratinocyte killing in the
context of parasite-induced skin inflammation. FasL signalling resulting in recruitment of activated neutrophils into dermis
may lead to destruction of the basal membrane and thus allow direct FasL mediated killing of exposed keratinocytes in vivo.
Based on our results we suggest that therapeutic inhibition of FasL and TRAIL could limit skin pathology during CL.
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Introduction
Leishmaniasis is a group of parasitic diseases associated with
heterogeneous clinical manifestations. Symptoms range from
lethal disease with overwhelming infection of the bone-marrow,
spleen and liver to localised self-healing ulcers of the skin.
Leishmania aethiopica is the main causative agent of CL in the
highlands of Ethiopia. Upon infection, parasites reside and
replicate within tissue macrophages during an initial silent phase
of the infection and the clinical presentation of CL is mainly
associated with the infiltration of circulating inflammatory cells
into infected tissues. L. aethiopica infection leads to localised
cutaneous leishmaniasis (LCL) or diffuse cutaneous leishmaniasis
(DCL). LCL is characterised by erosive ulcers and a strong T cell
mediated response [1] which typically results in spontaneous
healing within a year, scar formation and solid protection against
re-infection [2]. In contrast, DCL is linked to non-ulcerative
chronic nodular disease with abundant parasitic infiltration of the
dermal compartment of the skin and antigen specific T cell
unresponsiveness [3,4]. Structural differences [5] as well as
different immunogenic properties [4,6] between LCL and DCL
causing parasites have been reported. The mechanisms of tissue
destruction during ulcerative cutaneous leishmaniasis have not
been fully clarified. We have previously reported that dermal FasL
and TRAIL expressing cells are present in ulcerative L. major
infection and that the number of FasL expressing dermal cells
correlate to the level of epidermal apoptosis. Furthermore, in vitro
experiments propose FasL and TRAIL as major players inducing
apoptosis in keratinocytes during Leishmania induced inflammation
[7,8].
In the present study expression of FasL and TRAIL within the
skin was investigated in ulcerative and non-ulcerative manifesta-
www.plosntds.org 1 October 2010 | Volume 4 | Issue 10 | e844tions of L. aethiopica induced CL. More FasL and TRAIL
expressing cells were detected in ulcerative self-healing LCL as
compared to non-ulcerative chronic DCL. In line with these
results, neutralisation of FasL and TRAIL in vivo during
experimental leishmaniasis in BALB/c mice led to reduction of
ulceration and was not associated with increased infective loads or
increased spread of the infection through the lymphatics.
Materials and Methods
Ethical statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Ethical Review Board of Karolinska Institutet
(reference number 31-5427/08) and by The National Ethical
Clearance Committtee (NECC) at the Ethiopia Science and
Technology Commission (reference number: RDHE/78-43/
2002). All patients provided written informed consent for the
collection of samples and subsequent analysis. All animals were
handled in strict accordance with good animal practice as defined
by the relevant national animal welfare bodies, and this study was
approved by the Regional Animal Studies Ethical Committee,
Stockholm North, Sweden (reference number N72/05 and
305/08).
Patient material
Skin biopsies were collected from healthy controls at St.Paulos
General, Specialized Hospital, Addis Ababa, Ethiopia, and from
Ethiopian CL patients at the Armauer Hansen Research Institute
(AHRI), Addis Ababa, Ethiopia.
Immunohistochemistry of skin biopsies
FasL and TRAIL were visualised in formalin fixed tissue as
previously described [7,8] and evaluated in Leica fluorescent
microscope. Photomicrographs were obtained using a Zeiss
Axioskope 2, AxioVision 4.6 (Zeiss) and processed using Photo-
shop CS4. Apoptosis was assessed through visualizing fragmented
DNA using TUNEL (TdT-mediated dUTP nick end labeling) kit
according to the manufacturer’s instructions (Roche, Penzberg,
Germany). The number of FasL expressing cells was counted in
256objective and apoptotic cells were counted in 406objectives,
with more than ten fields evaluated per sample. A scoring system
for the wide-spread TRAIL expression found was used as shown in
Figure S1 and all samples were evaluated blindly.
Induction of keratinocyte apoptosis in vitro
Leishmania promastigotes propagated from ulcerative and non-
ulcerative lesions were used to stimulate healthy peripheral blood
mononuclear cells (PBMC) for 7 days at 1:1 ratio and supernatants
were collected and cryopreserved. Supernatants were added to
cultures of the keratinocyte cell-line HaCaT [9] for 20 hrs and
early apoptotic cells were assessed by AnnexinV/Propidium
Iodide staining by microscopy. Fas-activating monoclonal anti-
body (1 mg/ml, CH-11; MBL, Nagoya, Japan) and recombinant
TRAIL (250 ng/ml, R&D Systems) were used as positive controls.
Fas-blocking monoclonal antibody ZB4 (1-2 mg/ml, MBL) and
TRAIL-blocking antibody 2E5 (2.5 mg/ml, Alexis, KeLab,
Gothenburg, Sweden) were added 30 minutes prior to superna-
tants. Isotype control antibodies to CH-11, ZB4 or 2E5 did not
affect keratinocyte apoptosis. Apoptosis was assessed by counting
10 to 20 fields under 640 ocular magnification and expressed as
the number of apoptotic cells per 10 fields.
In vivo model of murine ulcerative leishmaniasis
Infective-stage metacyclic promastigotes of L. major (strain
Friedlin V1 or LV39, both gift from David Sacks, NIAID, NIH,
Bethesda, USA) were isolated from stationary cultures (4–5 days
old) by negative selection using peanut agglutinin (Vector
Laboratories, Burlingame, CA, USA) as previously described [10].
Mice
Female BALB/c aged 6–8 weeks were infected intradermally with
5610
4 metacyclic L. major [11]. Neutralising hamster anti-mouse
FasL (MFL-4) [12], rat anti-mouse TRAIL (N2B2) [13] or isotype-
matched hamster or rat IgG control (Rockland) were injected i.p. at a
dose of 0.5 mg twice per week for 4–5 weeks after infection. The
evolution of the lesion was monitored weekly by measuring the
diameter of the indurations of the ear lesion with a direct-reading
vernier caliper (Thomas Scientific, Swedesboro, NJ, USA). After
euthanization both ears and retromaxillar lymph nodes were
removed. Groups of five mice were infected at three (MFL-4 and
isotype-control) and two (N2B2 and isotype-control) different times.
Estimation of parasite load in ear and retromaxillar lymph
nodes
Parasite titrations were performed as previously described [11].
The number of viable parasites in each sample was defined as the
highest dilution at which promastigotes could be grown out after 7
days of incubation at 26uC.
Composition of cellular infiltrate and IFN-c production in
ear and lymph node
Single cell suspension of ear and lymph node tissue was
prepared as previously described [11]. Cells were stained ex-vivo
for Ly6C-PerCP, CD11b-APC, CD11c-FITC, FasL-PE, (all from
BD Biosciences) and CD45-eFluor 450 (eBioscience) Dead cells
were excluded by YFD conjugated Live/Dead stain kit (Molecular
Probes).
To assess IFNc producing cells, single cell suspension from ear
and lymph nodes were cultured over night (18 hours) in the
Author Summary
Cutaneous leishmaniases are associated with parasite-
induced inflammatory lesions of the skin. The degree of
clinical pathology is not associated with parasitic burden;
on the contrary, ulcerative lesions are associated with low
infectious load, and non-ulcerative lesions are associated
with an abundant parasite infiltration. Leishmania are
intracellular parasites in mammalian hosts and reside in
macrophages in the deep layers of the skin, the dermis.
The exact mechanism of ulceration in CL is not known and
Leishmania parasites do not directly induce destruction of
keratinocytes in the most superficial layer of the skin, the
epidermis. In this study we investigated if ulcerated lesions
were associated with higher expression of FasL- and TRAIL-
induced cell-death of keratinocytes. We found a higher
expression of FasL and TRAIL in human skin samples from
ulcerative as compared to non-ulcerative leishmaniasis. In
a mouse model of ulcerative leishmaniasis neutralisation of
FasL and TRAIL reduced ulceration. We suggest that FasL
and TRAIL participate in the ulcer formation during
leishmaniasis both as a chemoattractant of activated
neutrophils leading to tissue destruction and through
direct killing of keratinocytes. Possible approaches to use
this concept in therapeutical interventions with the aim to
reduce immunopathology associated with leishmaniasis
are discussed.
Death Ligands in Ulcerative Leishmaniasis
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described [11]. GolgiStop (BD Biosciences) was added during the
last 4 hours of culture. Cells were stained for TCRb-FICT, CD8-
PerCP, IFNc-APC (BD Biosciences) CD45- eFluor 450, CD4-
PECy7 (eBioscience) and Live/Dead (Molecular Probes). 20% (ex
vivo staining) and 30% (cytokine restimulation) of the total number
of cells per ear and 500 000 events from lymph nodes were
acquired on CyAn (Beckman Coulter) and analyzed by FlowJo 8
(Tree Star Inc).
Statistical analysis was performed using Prism Graph Pad
Software (Inc. Oberlin Drive, San Diego, USA).
Results and Discussion
Clinical presentation of ulcerative and non-ulcerative CL
Skin biopsies from ulcerative (n=19), non-ulcerative (n=13) and
healthycontrols(n=8)werecollectedatArmauerHansenResearch
Institute and at St. Paulos General Specialized Hospital, both Addis
Ababa, Ethiopia. Lesions were designated as ulcerative or non-
ulcerative according to clinical presentation (Fig. 1A and 2A). The
duration of ulcerative and non-ulcerative lesions was partly
overlapping with a median clinical history of lesion formation of 6
vs. 44 months at the time of biopsy (Fig. 1B). All included
individuals displaying the non-ulcerative phenotype had lesions in
several distinct parts of the body whereas ulcerative disease was
confined to a single lesion predominately on the face (Fig. 1A).
Leishmaniainfectionwasverified bydetectionofamastigotesbyMay-
Gru ¨nwald-Giemsa staining or by detection of viable promastigotes
in cultures of lesion scrapings. Non-ulcerative lesions contained
numerous disorganised macrophages laden with Leishmania amas-
tigotes, few lymphocytes and marked plasma cell infiltration, while
ulcerative lesions displayed fewer parasites and organised dermal
granulomas with prominent infiltration of lymphocytes and
epithelioid cells as previously described [3].
Dermal infiltration of FasL and TRAIL expressing cells
was more prominent in ulcerative as compared to
non-ulcerative CL
FasL was not expressed in healthy skin (Fig. 2B) and FasL was
not upregulated in epidermal cells during CL. FasL expressing
dermal cells were present in both ulcerative and non-ulcerative
leishmaniasis and accumulated close the ulcerated epidermis as
Figure 1. Clinical presentation of non-ulcerative and ulcerative
CL. (A) Clinical characteristics of non-ulcerative and ulcerative CL at the
time of sample collection. Median and the interquartile range (IQR) are
shown. (B) Dot-plot diagram depicting disease duration of non-
ulcerative and ulcerative CL at the time of biopsy. The horizontal bar
represents the median disease duration.
doi:10.1371/journal.pntd.0000844.g001
Figure 2. FasL and TRAIL expressing cells infiltrate dermis of
ulcerative CL. (A) Photographs of representative non-ulcerative
(center) and ulcerative (right) lesions of CL caused by L. aethiopica.
Control skin (left) was obtained from a fore arm, non-ulcerative from a
facial lesion and the ulcerative lesion from a fore arm. (B) FasL
expressing cells (DAB, brown) in healthy and lesional skin depicted and
counterstained with hematoxilin (blue). The upper row was taken using
a1 0 6objective and scale bars represent 100 micrometers. The lower
row show high magnification (406objective) of FasL expressing cells in
dermis. The ulcerated area is marked. (C) TRAIL expressing cells (DAB,
brown) counterstained with hematoxilin (blue). (D) Enumeration of
dermal FasL+ cells by counting of 10–20 fields per sample at 256
magnification. (E) Dermal TRAIL expression was assessed using an
arbitrary scale where 0 represented no signal and 5 represented
maximal signal. ***p,0.001, **p,0.01, *p,0.05, ns=not significant.
doi:10.1371/journal.pntd.0000844.g002
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detected in deep dermis of non-ulcerative CL but at significantly
lower levels as compared to ulcerative lesions (Fig. 2B and D).
The level of TRAIL expression was scored using an arbitrary
scale shown in Supplementary figure S1. Low or moderate TRAIL
expression was detected in healthy epidermis. As previously shown
[8], TRAIL expression was increased in epidermis of both LCL
and DCL as compared to healthy controls with no significant
difference in TRAIL expression between DCL and LCL (results
not shown). TRAIL expressing cells were also present in dermis of
both ulcerative and non-ulcerative L. aethiopica induced CL with
significantly higher expression in dermal inflammatory areas in
ulcerative as compared to non-ulcerative lesions (Fig. 2C and E).
We were not able to phenotype the TRAIL or FasL expressing
cells due to the lack of access of cryopreserved skin tissue. The
formalin, paraffin embedded skin biopsies used in this study
display abundant auto-fluorescence and could not be used for
multi-fluorochrome labelling and detection of double positive cells
by confocal microscopy. Previously, Mustafa et al reported that
macrophages in L. aethiopica induced CL express FasL [14]. In
ulcerative CL caused by L. major, we have previously shown
infiltration of FasL expressing T cells and macrophages were
present in dermis in cryopreserved skin biopsies [7].
Variable levels of epidermal apoptosis were detected in
lesion biopsies
To determine if the increased expression of TRAIL and FasL
correlated to increased keratinocyte apoptosis ex vivo, TUNEL
staining was performed on biopsies from ulcerative and non-
ulcerative leishmaniasis. Previously TUNEL staining on human
epidermis showed the same pattern of staining as caspase-cleaved
cytokeratin 18, verifying that TUNEL can be used as a marker of
apoptosis in Leishmania infected skin [7]. The number of epidermal
apoptotic cells showed great inter-individual variation in all groups
examined (Fig. 3A and B) and ulcerative lesions did not contain
significantly higher numbers of epidermal apoptotic cells as
compared to non-ulcerative lesions and healthy skin. However,
there was a clear trend to a higher number of apoptotic
keratinocytes in the ulcerative group. We have previously shown
an increase in the number of apoptotic epidermal cells in L. major
caused ulcerative disease as compared to healthy skin in a cohort
of young military recruits with a history of ulcerative leishmaniasis
of less than three months upon transfer into a hyperendemic
Leishmania foci [7]. In the present hospital based study the patient
material was collected from a heterogeneous group of patients
from endemic areas and the median duration of the disease at the
time of tissue collection was longer. Furthermore, infection with L.
major typically leads to more aggressive tissue destruction as
compared to L. aethiopica caused infection. Due to the immediate
and efficient clearance of apoptotic cells in vivo by phagocytic cells
such as tissue macrophages, the level of apoptotic cells detected in
ex vivo biopsies may not reflect the amount of cell death taking
place in the tissue. Thus we utilised an in vitro experimental set-up
in which keratinocytes were exposed to Leishmania derived
supernatants in the absence of phagocytic cells.
Induction of keratinocyte apoptosis upon exposure to
supernatants from peripheral blood mononuclear cells
(PBMCs) stimulated with parasites collected from
ulcerative CL
It has been postulated that distinct subtypes of L. aethiopica
induce ulcerative and non-ulcerative disease through differential
immune-activating properties. To test the apoptosis inducing effect
of parasites derived from ulcerative and non-ulcerative lesions,
parasites from the different clinical manifestations of CL were
obtained from clinical lesions and propagated in vitro. Infective
promastigotes were used to stimulate PBMC from healthy
individuals for seven days and supernatants from such cultures
were added to an immortalised keratinocyte cell line sensitive to
anti-Fas and TRAIL induced killing (Fig. 4A and B) in which Fas
blocking and TRAIL neutralising antibodies completely inhibits
apoptosis (Fig. 4D). Leishmania promastigotes alone did not induce
keratinocyte apoptosis (results not shown) and implicating that the
immune activation induced by the parasitic infection was
necessary to induce killing of keratinocytes. Supernatants derived
from LCL stimulated PBMCs induced significantly more kerati-
nocyte apoptosis as compared to unstimulated PBMC or PBMC
stimulated with DCL derived parasites (Fig. 4A and C).
Furthermore, keratinocyte apoptosis induced by supernatants
from LCL infected PBMC could be inhibited by the addition of
Fas blocking antibodies (Fig. 4E) or TRAIL blocking Abs (Fig. 4F).
The isotype controls corresponding to TRAIL and Fas blocking
antibodies did not have any effect on keratinocyte apoptosis. No
synergistic effect was noted when both FasL and TRAIL were
inhibited simultaneously (Fig. 4G). The low level of keratinocyte
apoptosis induced by supernatants from DCL infected PBMCs
could be reduced with TRAIL blocking antibodies but not with
Fas blocking antibodies (Fig 4 E–F). TRAIL but not FasL is
expressed on HaCaT and the levels of TRAIL increase during
exposure to inflammatory supernatants. Possibly TRAIL, but not
Fas, blocking antibodies may prevent keratinocyte-keratinocyte
killing in the context of mild inflammation.
Short-term neutralisation of FasL and TRAIL decreased
the immunopathology without affecting the infectious
burden in a murine model of ulcerative CL
Current treatment alternatives during active CL are aimed at
parasite eradication [2] and have little effect on tissue destruction.
On the contrary, current treatment regimes result in exacerbation
of inflammation leading to increased tissue destruction and
Figure 3. Apoptosis in skin biopsies from ulcerative and non-
ulcerative CL. (A) TUNEL staining depicting apoptotic cells (orange) in
healthy control (left), non-ulcerative (central) and ulcerative (right) CL.
The basal membrane separating epidermis and dermis is marked with a
dashed white line. Dot plot showing the number of epidermal (B) and
dermal (C) apoptotic cells. The horizontal bar represents the median. No
significant differences in number of apoptotic cells were found in the
groups investigated.
doi:10.1371/journal.pntd.0000844.g003
Death Ligands in Ulcerative Leishmaniasis
www.plosntds.org 4 October 2010 | Volume 4 | Issue 10 | e844Figure 4. Supernatants from PBMCs stimulated with parasites from LCL patients, but not from DCL patients, induce apoptosis in
keratinocytes through FasL and TRAIL signalling. (A) Bright phase photographs (left panel) and AnnexinV (green) plus Propidium Iodide (red)
staining (right panel) of monolayers of keratinocytes 20 hrs after addition of anti-Fas (CH11), recombinant TRAIL or supernatants from PBMCs
stimulated with promastigotes propagated from ulcerative (LCL) or non-ulcerative (DCL) lesions. CON represents supernatants from unstimulated
PBMC and ‘‘media alone’’ keratinocytes in normal media. The pictures depicted did not contain any necrotic cells and thus no Propidium Iodine
staining (red) is visible. (B) Dot plot showing induction of keratinocyte apoptosis by addition of anti-Fas (CH11) or recombinant TRAIL. (C) Dot plot
showing induction of keratinocyte apoptosis by addition of supernatants from parasite stimulated PBMC cultures as in (A). The horizontal bar
represents the median value. (D) Plots showing the inhibitory effect of the Fas blocking antibody ZB4 (1–2 mg/ml) and the TRAIL blocking antibody
2E5 (25 mg/ml) on CH11 (1 mg/ml) and TRAIL (250 ng/ml) induced apoptosis (n=9). (E–G) Blocking effect of ZB4 and 2E5 on apoptosis induced by
DCL (n=10) and LCL (n=16) cultures. ***p,0.001, **p,0.01, *p,0.05, ns=not significant.
doi:10.1371/journal.pntd.0000844.g004
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a promising new approach for the therapy of cancer and
autoimmune diseases. We were interested to investigate if such
approach could be used to decrease the pathology caused by a
protozoan infection such as Leishmania infection.
The effect of systemic treatment with FasL and TRAIL
neutralising antibodies during the ulcerative process during CL
was investigated. L. aethiopica inoculation in mice does not lead to
productive infection or ulcerative disease. Thus L. major, causing
ulcerative leishmaniasis, was used throughout the in vivo experi-
ments. C57BL/6 inoculated with L. major developed non-
ulcerative lesions followed by self-healing and was thus not a
suitable model to follow ulcer development. Addition of sandfly
salivary gland homogenate to low dose L. major infection in
C57BL/6 mice, as previously described [15], did not cause stable
and reproducible ulcer development suitable for our purpose and
was not pursued beyond pilot experiments. High dose infection in
C57BL/6 (Jackson strain) mice bred at Karolinska Institutet
caused non-ulcerative lesions followed by necrotic degradation of
the ear tissue. Thus, a well-characterised model of ulcerative CL
using a low number of metacyclic L. major promastigotes injected
intradermally into the ear of BALB/c was chosen [16] despite the
Th2 bias and strong IL-4 production associated with this model.
Systemic treatment with FasL [12] or TRAIL [13] blocking
antibodies was given twice weekly. Hamster and rat isotype control
antibodies were given in parallel and there was no difference in
ulcer development between the different isotype control antibodies
used (results not shown). A clear reduction in the development of
ulcers was noted in the treated animals as compared to hamster
isotype control treatment (Fig. 5A–C). In spite of reduction of
ulceration, neutralisation of FasL or TRAIL was not sufficient to
completely inhibit ulcer formation and no synergistic effect was
noted by the simultaneous administration of FasL and TRAIL
neutralising antibodies.
Insufficient clearance of L. major infection has previously been
shown in Fas and FasL deficient mice and the treatment strategy
used could potentially lead to uncontrolled parasite replication.
Impaired control of parasite replication has been shown in Fas and
FasL deficient mice [17–19] and systemic administration of
exogenous recombinant FasL to FasL deficient (gld) mice led to
elimination of parasites and resolution of cutaneous non-ulcerative
lesions [17]. In vitro studies have shown that macrophages infected
with L. major up-regulate their surface Fas expression in response to
IFN-c and as a result become susceptible to CD4+ T cell- induced
apoptotic death [17]. No data is available on the evolution of
Leishmania induced pathology in TRAIL deficient mice. Based on
the previous studies in FasL deficient mice, there is a potential risk
to exacerbate parasite replication through inhibition of FasL
during ulceration. In the model of ulcerative leishmaniasis used in
these studies, systemic neutralisation of FasL and TRAIL did not
affect increased infectious loads at the primary site of infection
(Fig. 5D).
Likewise, the infectious load in the draining lymph node was not
altered during treatment, suggesting that dissemination of the
infection was not enhanced by short-term neutralisation of Fas/
FasL and TRAIL-Rs/TRAIL in this model of CL induced by a
low dose of infective parasites.
Using a different strain of L. major (LV39) did not lead to ulcer
development (Fig. S2 A–C) despite similar parasite loads in ears
and draining lymph nodes. Interestingly, the area of inflamed skin
surrounding the site of infection was reduced whereas the parasite
loads were not affected in mice treated with FasL neutralising
antibodies, thus mirroring the results obtained using the ulcerative
model induced by L. major strain Friedlin V1.
There are several potential explanations to why effect of FasL
on parasite loads obtained in this report differs from earlier studies.
The data previously published was obtained using a different route
of inoculation, a different infectious dose and different genetic
backgrounds of the host mice. The Fas (lpr) deficient transgenic
mice show a profound lymphoproliferative phenotype with half
the life expectancy as compared to congenic control mice [20].
Due to alterations in the thymic selection of T cells these mice
display a skewed T cell repertoire that in itself may affect the
ability to combat parasitic disease independently of peripheral
FasL signalling during infection. In contrast, we chose to use short-
term inhibition of FasL and TRAIL in immuno-competent mice.
Antigen specific IFN-c production is not altered upon
FasL neutralisation during ulcerative leishmaniasis in
BALB/c mice
IFN-c production by CD4 cells has been ascribed a critical role
in parasite clearance during leishmaniasis through activation of
infected macrophages. Although the number of CD4+ T cells, and
to a lesser extent the CD8+ T cells, were reduced at the site of
infection during FasL neutralisation (Fig. S3A–C), the ratio
between CD4:CD8 T cells was identical to control infected mice.
The percentage of IFN-c producing CD4+ T cells at the site of
infection was not affected by FasL neutralisation as shown in
Figure S3D and further antigen stimulation did not enhance the ex
Figure 5. Blocking FasL and TRAIL reduce ulceration during
experimental CL. (A) Photograph of L. major (strain Friedlin V1)
infected ears 4 weeks post infection treated with hamster isotype
control (upper row) or anti-FasL neutralising Abs (MFL4, lower row). The
right panel depict the diameter of the ulcerated area (line) and the
outline of the inflamed, lesional area (circle). (B) Development of ulcer in
L. major infected BALB/c mice during the treatment with hamster
isotype control, anti-FasL (MFL4) or anti-TRAIL (N2B2) was followed over
time. The experiment was repeated twice and the pooled results of a
total of 14 samples per treatment regime are shown. Mean and
standard error of the mean is depicted. (C) Dot-plot diagram showing
individual measurements of ulcer size at four weeks after infection. (D)
Dot plot diagram showing parasite loads from ears and lymph nodes at
four weeks after the infection. Six samples from a representative
experiment repeated two times with similar results are depicted.
***p,0.001, *p,0.05, ns=not significant.
doi:10.1371/journal.pntd.0000844.g005
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amounts of parasitic antigen and antigen presenting cells present
in the single cell suspension prepared from ear tissue. In line with
the finding that FasL neutralisation did not affect the parasitic
load, CD4+ T cell antigen-specific IFN-c production was not
affected by FasL neutralisation as shown in figure S3 E–F.
It has recently been reported that FasL may potentiate the effect
of IFN-c signalling in macrophages, leading to more efficient
parasite eradication [21]. This effect was prevented in the presence
of IL-4 and we cannot exclude that the lack of effect, on the
infectious load during FasL neutralisation was influenced by the
high levels of IL-4 production in BALB/c mice. Taken the lack of
a reliable ulcerative leishmaniasis model on a different genetic
background, this concern could not be addressed in the present
study.
Recruitment of neutrophils into sites of infection is
reduced during systemic FasL neutralisation
The mechanisms behind ulceration during cutaneous leishman-
iasis are not understood. Necrotic death due to intense
inflammation is probably one cause of ulceration during
leishmaniasis, but publications on the subject are scarce. In a
therapeutic attempt to administer IFN-c during human CL to
enhance parasite killing, side effects in terms of pronounced
inflammation was noted [22] and it has been postulated but not
properly proven that inflammation leading to tissues destruction is
necessary for treatment control. In addition to the pure apoptosis
inducing effect of FasL, proinflammatory effects of FasL signalling
has been proposed in a number of different settings and in
macrophages resistant to FasL mediated killing, FasL signalling
leads to TNFa and IL-8 secretion potentially leading to
recruitment of neutrophils into sites of infection. Interestingly,
neutrophils are recruited into the site of infection during cutaneous
leishmaniasis in humans [23,24] and in mice accumulation of
neutrophils have been linked to tissue damage [25]. In the latter
study, IL-17 was shown to be the major neutrophil chemoat-
tractant during infection.
To test if FasL neutralization leads to an impaired recruitment of
neutrophils into the infected skin we enumerated the number of
neutrophils and macrophages during FasL neutralisation in parallel
to control treated mice. A two-fold reduction in the number of
neutrophils was found during FasL neutralisation (Fig 6). Similar
results were found in the non-ulcerative model of leishmaniasis
obtained by L. major (strain LV39) as shown in figure S2. It is
possible that a complete block of neutrophils into the site of
infection, possibly through targeting IL-17 and FasL simultaneous-
ly, would further reduce the ulceration. However, in the context of
infection potentially tissue damaging cells (e.g. neutrophils) may be
necessary for parasite control. Neutrophils are rapidly recruited to
thesite ofinfectionaftera sand-fly bite andserveasa firsthostcellto
Leishmania promastigotes. Neutrophils undergo spontaneous apop-
tosis within days in peripheral tissues and as Leishmania infected, it
has been shown neutrophils can facilitate infection [26]. However,
in later stages of infection neutrophils probably play a role in
controlling the infection through their strong inflammatory, and
tissue destructive, function and through activation of Leishmania
infected macrophages [27–29].
In this report, we show that FasL and TRAIL expressing cells
infiltrate dermis and that a higher level of expression is present
during ulcerative leishmaniasis as compared to non-ulcerative
leishmaniasis. In vitro experiments confirmed that FasL and
TRAIL neutralising antibodies directly inhibit keratinocyte
apoptosis in the context of Leishmania induced inflammation. The
potential role of FasL and TRAIL during Leishmania induced
ulceration was further strengthened by the reduction of ulceration
during systemic neutralisation of both FasL and TRAIL in a
murine model of ulcerative leishmaniasis. FasL neutralisation in
vivo led to a reduction in the recruitment of neutrophils into the site
of infection, suggesting additional pro-inflammatory mechanisms
of FasL signalling during leishmaniasis.
The results shown here, obtained from human samples and
murine in vivo experiments, suggest at least two different roles for
FasL during skin ulceration in Leishmania infection. Firstly, FasL
signalling in the inflamed tissue is involved in neutrophil
recruitment. Secondly, sFasL induce keratinocyte death. Activated
neutrophils are tissue destructive and one can envisage a scenario
where neutrophils cause destruction of the basal membrane in
areas of intense infection. Through breaking the epidermal-dermal
border soluble death ligands get access to keratinocytes leading to
direct destruction of the epidermis and ulceration.
Fas-FasL interactions have been implicated in the pathogenesis
of drug-induced toxic epidermal necrolysis (TEN), a life-threaten-
ing disease characterized by extensive destruction of epidermal
keratinocytes [12,13]. Systemic treatment with intravenous
immunoglobulins containing Fas-blocking antibodies limited the
ulcerative process during TEN [13] and reduced mortality in
several multi-centre analysis. In the case of CL we propose that an
adjuvant therapy neutralizing FasL or TRAIL in combination
with leishmanicidals could reduce the ulcerative process and
subsequent scar formation.
Supporting Information
Figure S1 Assessment of TRAIL staining in skin biopsies.
Representative pictures of TRAIL stainings (DAB, brown) were
used to blindly assess the level of TRAIL expression in skin
biopsies. Depicted from the left: 1) isotype control 2) healthy skin
3) non-ulcerative leishmaniasis 4–5) ulcerative leishmaniasis.
Found at: doi:10.1371/journal.pntd.0000844.s001 (1.97 MB TIF)
Figure S2 FasL neutralisation in a non-ulcerative model of CL.
(A) Photograph of naive (top row), L. major (strain LV39) infected
ears 5 weeks post infection treated with Hamster IgG (mid row) or
Figure 6. FasL neutralisation lead to reduction of neutrophil
migration into Leishmania infected skin. (A) Representative FACS
plots of single cell suspension gated on live CD45+ cells. Neutrophils
were identified as Ly6
highCD11b
high cells. Monocyte/macrophages were
identified as Ly6
int/low CD11b
high cells. (B) Bar graph showing the
number of neutrophils in naive and Leishmania infected ears. (C) Bar
graph showing the number of monocyte/marophages per ear. Eight
samples from two separate experiments were pooled four weeks post
infection. Mean and SEM are shown.
doi:10.1371/journal.pntd.0000844.g006
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www.plosntds.org 7 October 2010 | Volume 4 | Issue 10 | e844anti-FasL neutralising antibodies (bottom row). (B) Dot plot
diagram showing individual measurements of non-ulcerated lesion
size five weeks post infection. (C) Dot plot diagram showing
parasite loads from ears and lymph nodes five weeks after
infection. Horizontal bars represents median (D) Representative
FACS plots of single cell suspension from ear tissue stained for
CD45-eFlour450 and Live/Dead YFP. (E) Bar graph showing the
number of viable CD45+ cells assessed by FACS analysis of single
cell suspension from infected ears. (F) Bar graphs depicting the
number of live, CD45+ neutrophils five weeks post infection.
*,p,0–05 ** p,0.01. 6–8 samples pooled from two separate
experiments are depicted. Mean and standard error of the mean
depicted.
Found at: doi:10.1371/journal.pntd.0000844.s002 (0.49 MB TIF)
Figure S3 T cell infiltration but not IFNc production are
affected by FasL neutralisation. (A) Representative FACS plots of
CD4+ and CD8+ T cells gated on live CD45+ TCRb+ cells from
Leishmania infected ears four weeks post infection treated with
isotype control (left panel) or antiFasL antibodies (right panel). (B)
The number of CD8+ T cells per ear (right panel) and the
percentage of CD8+ T cells of total TCRb+ cells. Four samples
from one representative experiments is depicted, in total eight
samples were analysed. (C) The number of CD4+ T cells per ear
(right panel) and the percentage of CD4+ T cells of total TCRb+
cells. Four samples from one representative experiments is
depicted, in total eight samples were analysed. (D) Representative
FACS plots of IFNc production in live CD45+TCRb+CD4+ cells
four weeks post-infection. (E–F) Representative FACS plots of ex
vivo (left panel) and antigen dependent (right panel) IFN
cproduction in live CD45+TCRb+CD4+ cells four weeks post-
infection. Representative FACS plots of in total eight samples per
group performed in two separate experiments are shown.
Found at: doi:10.1371/journal.pntd.0000844.s003 (0.25 MB TIF)
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